Education
About Us
Working with TipRanks
Follow Us
Biomea Fusion (BMEA)
NASDAQ:BMEA
BMEA Stock Chart & Stats
$1.37
$0.07(1.75%)
At close: 4:00 PM EST
$1.37
$0.07(1.75%)
Day’s Range― - ―
52-Week Range$0.87 - $3.08
Previous CloseN/A
Volume309.16K
Average Volume (3M)2.40M
Market Cap
$96.86M
Enterprise Value$41.74M
Total Cash (Recent Filing)$46.64M
Total Debt (Recent Filing)$6.88M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Apr 06, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding70,703,636
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-1.16
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-83.49
Enterprise Value/Ebitda-0.44
Forecast
1Y Price Target
$6.00Price Target Upside337.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyClinical data showed durable improvements in blood sugar control and sustained C‑peptide increases up to 52 weeks, supporting a potential disease‑modifying effect through restoration of beta‑cell function.
Pipeline ExpansionPipeline expansion with a next‑generation candidate entering early human testing increases potential treatment options for diabetes and obesity and diversifies clinical upside.
Regulatory Development PathConfirmatory mid‑stage trials are planned in defined type 2 diabetes subgroups to support regulatory approval for later‑stage development, providing a clearer path toward commercialization.
Bears Say
Binary Trial Outcome VolatilityBinary nature of confirmatory and early‑stage trial outcomes could trigger significant stock volatility if efficacy or safety endpoints are not met.
Clinical And Regulatory Execution RiskValuation depends heavily on successful execution of confirmatory and early‑stage studies, creating substantial clinical and regulatory risk that could affect approval prospects.
Early‑stage Program UncertaintyEarly human testing for the next‑generation candidate carries inherent safety and efficacy uncertainty, which could limit upside if results fall short of expectations.
Biomea Fusion News
BMEA FAQ
What was Biomea Fusion’s price range in the past 12 months?
Biomea Fusion lowest stock price was $0.87 and its highest was $3.08 in the past 12 months.
What is Biomea Fusion’s market cap?
Biomea Fusion’s market cap is $96.86M.
When is Biomea Fusion’s upcoming earnings report date?
Biomea Fusion’s upcoming earnings report date is Apr 06, 2026 which is in 34 days.
How were Biomea Fusion’s earnings last quarter?
Biomea Fusion released its earnings results on Nov 04, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.256 by -$0.014.
Is Biomea Fusion overvalued?
According to Wall Street analysts Biomea Fusion’s price is currently Undervalued.
Does Biomea Fusion pay dividends?
Biomea Fusion does not currently pay dividends.
What is Biomea Fusion’s EPS estimate?
Biomea Fusion’s EPS estimate is -0.23.
How many shares outstanding does Biomea Fusion have?
Biomea Fusion has 70,703,636 shares outstanding.
What happened to Biomea Fusion’s price movement after its last earnings report?
Biomea Fusion reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.256. Following the earnings report the stock price went up 6.349%.
Which hedge fund is a major shareholder of Biomea Fusion?
Currently, no hedge funds are holding shares in BMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biomea Fusion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (337.96% Upside)
$6.00 (337.96% Upside)
Insider Transactions
Bought Shares
Worth $196.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.77%
12-Months-Change
Fundamentals
Return on Equity
-209.00%
Trailing 12-Months
Asset Growth
-46.27%
Trailing 12-Months
Company Description
Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
BMEA Stock 12 Month Forecast
Average Price Target
$6.00
▲(337.96% Upside)
Technical Analysis
Ownership Overview
8.85% Insiders
11.06% Mutual Funds
4.15% Other Institutional Investors
72.13% Public Companies and
Individual Investors